NCT02616445 - Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy Volunteers

Interventions

DRUG

UE2343

"* UE2343~* 10mg, 20, 35mg~* twice daily for 9 days"

DRUG

Placebo

"* 10mg, 20, 35mg~* twice daily for 9 days"

DRUG

Placebo

"* Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"

DRUG

UE2343

"* Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"

DRUG

UE2343

"* UE2343~* twice daily for 3 days~* single dose on day 4"

Trial Locations (1)

Linear Clinical Research, Nedlands